Show simple item record

dc.contributor.authorRossi, Omaren
dc.contributor.authorGrant, Andrewen
dc.contributor.authorMastroeni, Pietroen
dc.date.accessioned2017-03-27T14:43:59Z
dc.date.available2017-03-27T14:43:59Z
dc.date.issued2017-01-13en
dc.identifier.issn2049-632X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/263260
dc.description.abstractImmunity can co-operate with antibiotics, but can also antagonize drug efficacy by segregating the bacteria to areas of the body that are less accessible to antimicrobials, and by selecting for subpopulations with low division rates that are often difficult to eradicate. We studied the effect of an anti-inflammatory/immunosuppressive anti-TNFα treatment, which accelerates bacterial growth in the tissues and inhibits or reverses the formation of granulomas, on the efficacy of ampicillin and ciprofloxacin during a systemic Salmonella enterica infection of the mouse. The anti-TNFα treatment neither precluded not enhanced the efficacy of antibiotic treatment. However, the anti-TNFα treatment rendered the animals susceptible to the rapid relapse of the infection seen after cessation of the antibiotic treatment. Reactivation of an established infection, due to late administration of anti-TNFα antibodies, could be successfully controlled by antibiotics, but full clearance of the bacterial load from the tissues was not achieved. We conclude that the lack of TNFα does not preclude the efficacy of antibiotic treatment and must be monitored with care due to post-treatment relapses. Combinations of anti-cytokine compounds and antibiotic molecules may not be the best way to treat persistent infections with intracellular bacteria like Salmonella.
dc.description.sponsorshipThis work was supported by a Biotechnology and Biological Sciences Research Council [grant number BB/M000982/1].
dc.languageengen
dc.language.isoenen
dc.publisherOxford University Press
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectTNF-alphaen
dc.subjectSalmonellaen
dc.subjectantibioticen
dc.subjectin vivoen
dc.subjectampicillinen
dc.subjectciprofloxacinen
dc.titleEffect of in vivo neutralisation of Tumor Necrosis Factor alpha on the efficacy of antibiotic treatment in systemic Salmonella enterica infections.en
dc.typeArticle
prism.issueIdentifier1en
prism.publicationDate2017en
prism.publicationNamePathogens and Diseaseen
prism.volume75en
dc.identifier.doi10.17863/CAM.8586
dcterms.dateAccepted2017-01-12en
rioxxterms.versionofrecord10.1093/femspd/ftx002en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2017-01-13en
dc.contributor.orcidRossi, Omar [0000-0001-8492-2472]
dc.contributor.orcidGrant, Andrew [0000-0001-9746-2989]
dc.contributor.orcidMastroeni, Pietro [0000-0003-3838-4962]
dc.identifier.eissn2049-632X
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idBBSRC (BB/M000982/1)
cam.issuedOnline2017-01-13en
cam.orpheus.successThu Jan 30 12:56:32 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International